In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
about
The janus facet of nanomaterialsDisordering of human telomeric G-quadruplex with novel antiproliferative anthrathiophenedioneIntraductal therapy of ductal carcinoma in situ: a presurgery study.EGFR-mediated intracellular delivery of Pc 4 nanoformulation for targeted photodynamic therapy of cancer: in vitro studies.Innovative approaches for demonstration of bioequivalence: the US FDA perspective.Nanomedicine: a pharma perspective.Anti-Tumor Effects of Bak-Proteoliposomes against Glioblastoma.Effect of Nanoparticle Surface on the HPLC Elution Profile of Liposomal Nanoparticles.Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures.Loading and release mechanism of red clover necrotic mosaic virus derived plant viral nanoparticles for drug delivery of doxorubicin.Efficacy of antioxidants as a Complementary and Alternative Medicine (CAM) in combination with the chemotherapeutic agent doxorubicin.Effects of lipid composition on the properties of doxorubicin-loaded liposomes.
P2860
Q28083583-8F7B4940-9516-49D7-B755-B480B4C74E70Q28477964-B56BACCD-3CB5-4DA7-B39C-3A3A2B8D7FBDQ35637342-18FFF81B-5C44-42B2-BAB4-08A0C5E25D20Q35851952-44147230-E51D-4D8F-A1E6-F8B0A5FC6ABCQ38112172-13B632EC-DF72-4CF4-A97D-4A339C73454DQ38246663-F917D4C3-FFEB-4214-8DBA-34FAA0EF45E1Q38837839-F6A977B2-56DD-4352-ABE7-F64AD5852CE2Q38901696-BA05A5FF-EA5C-4B0C-8D58-D3B821A186B1Q38978632-C28722EC-AF21-44D4-8785-9B66DAD3E8A4Q42201613-0A935873-F352-4461-AE94-30BCE29EBCE8Q42831840-33FDAF85-CAC1-4A0E-B0F3-09ACB8C8B596Q52927166-7B167BAC-570D-41C5-B82C-F79B1C93B751
P2860
In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
@en
In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
@nl
type
label
In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
@en
In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
@nl
prefLabel
In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
@en
In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
@nl
P2093
P2860
P356
P1433
P1476
In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
@en
P2093
Lawrence X Yu
Robert Lionberger
Wenlei Jiang
P2860
P304
P356
10.4155/BIO.10.204
P577
2011-02-01T00:00:00Z